Trastuzumab resistance induces EMT to transform HER2(+) PTEN(−) to a triple negative breast cancer that requires unique treatment options

Although trastuzumab is an effective treatment in early stage HER2(+) breast cancer the majority of advanced HER2(+) breast cancers develop trastuzumab resistance, especially in the 40% of breast cancers with loss of PTEN. However, HER2(+) breast cancer patients continue to receive trastuzumab regar...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnett, Joseph P., Korkaya, Hasan, Ouzounova, Maria D., Jiang, Hui, Conley, Sarah J., Newman, Bryan W., Sun, Lichao, Connarn, Jamie N., Chen, Ching-Shih, Zhang, Ning, Wicha, Max S., Sun, Duxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629137/
https://www.ncbi.nlm.nih.gov/pubmed/26522776
http://dx.doi.org/10.1038/srep15821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629137/
https://www.ncbi.nlm.nih.gov/pubmed/26522776
http://dx.doi.org/10.1038/srep15821

Ejemplares similares